What is Concord Drugs share price return in the past 10 years?

Data is not available for this company

Concord Drugs Ltd - Stock Valuation and Financial Performance

Name: Concord Drugs
Brand: Concord Drugs

BSE: 538965 | NSE: | Pharmaceuticals & Drugs | Small Cap

Place order

Concord Drugs Share Price

₹37.59 0.55 1.48%
as on 24-Dec'24 16:59

DeciZen - make an informed investing decision on Concord Drugs

Based on:

Data

M-Cap below 100cr DeciZen not available

Concord Drugs stock performance -

PE Chart Key Ratios

P/E Ratio (SA):

0.00

Market Cap:

37.6 Cr.

52-wk low:

30.6

52-wk high:

61.5

Is Concord Drugs Ltd an attractive stock to invest in?

1. Is Concord Drugs Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Concord Drugs Ltd is a average quality company.

2. Is Concord Drugs Ltd undervalued or overvalued?

The key valuation ratios of Concord Drugs Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Concord Drugs Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Concord Drugs Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Concord Drugs:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	11.3%	15.9%	8.8%	7.5%	6.2%	6.1%	15.7%	9.3%	6%	4.5%	-
Value Creation Index ⓘ	-0.2	0.1	-0.4	-0.5	-0.6	-0.6	0.1	-0.3	-0.6	NA	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	40	50.7	57.5	51.8	48.1	51.3	51.4	59	51.3	43.3	45
Sales YoY Gr.	-	26.6%	13.4%	-9.9%	-7.2%	6.8%	0%	14.8%	-13%	-15.7%	-
Adj EPS ⓘ	1	2.5	0.2	0.4	0.5	0.4	0.7	1.8	1	0.4	-0.5
YoY Gr.	-	156.3%	-91.1%	86.4%	26.8%	-26.9%	94.7%	146%	-47.3%	-56.3%	-
BVPS (₹) ⓘ	18.4	20.8	26.2	24.6	29.5	26.9	30.6	32.4	33.4	33.8	33.9
Adj Net Profit ⓘ	0.7	1.8	0.2	0.3	0.4	0.3	0.7	1.6	0.9	0.4	-1
Cash Flow from Ops. ⓘ	1.8	3.6	1.7	6.9	1.2	2.5	1.6	0.8	2.2	2	-
Debt/CF from Ops. ⓘ	12.2	5.5	9.1	2	8.2	3.9	8	21.2	7	7.6	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	0.9%	-2.1%	-5.6%	-15.7%
Adj EPS ⓘ	-8.8%	-4.2%	-17.2%	-56.3%
BVPSⓘ	7%	2.8%	3.4%	1.2%
Share Price	-	23.7%	7.3%	-12.5%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	5	12.6	0.9	1.7	1.9	1.4	2.6	5.8	3	1.3	-1.5
Op. Profit Mgn % ⓘ	17.6	16.4	9.6	8.8	7.6	6.5	6.3	9.5	8.5	8.5	5.1
Net Profit Mgn % ⓘ	1.7	3.5	0.3	0.6	0.9	0.6	1.3	2.7	1.7	1	-1.2
Debt to Equity ⓘ	1.6	1.3	0.8	0.7	0.4	0.4	0.5	0.6	0.5	0.4	0.1
Working Cap Days ⓘ	272	263	251	474	620	416	293	241	296	348	160
Cash Conv. Cycle ⓘ	107	128	102	129	146	199	217	189	217	271	82

Recent Performance Summary

Debt to equity has declined versus last 3 years average to 0.50

Sales growth is good in last 4 quarters at 12.83%

Return on Equity is Poor

Sales growth has been subdued in last 3 years -0.02%

Latest Financials - Concord Drugs Ltd.

	Standalone	Consolidated
TTM EPS (₹)	-0.5	-0.5
TTM Sales (₹ Cr.)	45.3	52.5
BVPS (₹.) ⓘ	33.9	33.9
Reserves (₹ Cr.) ⓘ	24	24
P/BV ⓘ	1.11	1.11
PE ⓘ	0.00	0.00

From the Market
52 Week Low / High (₹)	30.59 / 61.50
All Time Low / High (₹)	11.68 / 91.25
Market Cap (₹ Cr.)	37.6
Equity (₹ Cr.)	10
Face Value (₹)	10
Industry PE ⓘ	44.4

Management X-Ray of Concord Drugs:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Concord Drugs

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Concord Drugs

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	40.02	50.68	57.49	51.80	48.08	51.34	51.36	58.96	51.31	43.26
Operating Expenses ⓘ	33	42.44	51.98	47.24	44.42	47.99	48.14	53.36	46.97	39.58
Manufacturing Costs	6.63	16.44	10.31	10.51	10	17.23	16.35	15.68	12.58	6.80
Material Costs	25.38	23.80	37.23	34.02	30.89	26.64	27.39	27.05	28.99	27.05
Employee Cost	0.44	1.61	2.57	1.73	2.29	3.27	3.47	4.14	3.55	3.87
Other Costs ⓘ	0.55	0.58	1.88	0.98	1.24	0.85	0.93	6.50	1.85	1.87
Operating Profit ⓘ	7.02	8.25	5.51	4.56	3.66	3.34	3.22	5.59	4.34	3.68
Operating Profit Margin (%)	17.5%	16.3%	9.6%	8.8%	7.6%	6.5%	6.3%	9.5%	8.5%	8.5%
Other Income ⓘ	0.37	0.20	0.15	0.37	0.09	0.12	0.09	0.10	0.01	0.01
Interest ⓘ	2.72	2.57	2.42	1.88	1.59	1.54	1.42	1.68	1.62	1.59
Depreciation ⓘ	3.63	2.91	2.58	2.40	1.71	1.46	1.37	1.76	1.60	1.54
Exceptional Items ⓘ	0	0	0	0	0	0	3.76	0	0	0
Profit Before Tax ⓘ	1.05	2.96	0.65	0.64	0.44	0.46	4.29	2.25	1.13	0.56
Tax ⓘ	0.35	1.21	0.49	0.31	0.03	0.13	1.01	0.66	0.23	0.14
Profit After Tax	0.70	1.75	0.16	0.32	0.41	0.33	3.28	1.59	0.89	0.42
PAT Margin (%)	1.7%	3.4%	0.3%	0.6%	0.8%	0.6%	6.4%	2.7%	1.7%	1.0%
Adjusted EPS (₹)	1.0	2.4	0.2	0.4	0.5	0.4	3.8	1.8	1.0	0.4
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	13.32	15.07	18.99	19.32	23.16	23.48	26.77	28.35	31.14	33.82
Share Capital ⓘ	7.24	7.24	7.24	7.86	7.86	8.74	8.74	8.74	9.32	10
Reserves ⓘ	6.07	7.82	11.75	11.46	15.29	14.74	18.02	19.61	21.82	23.82
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	21.27	19.99	15.44	12.41	9.83	9.57	12.97	15.65	14.80	14.01
Long Term Debt	12.64	12.21	6.18	3.41	0.69	0.88	3.75	1.70	1.02	0.03
Short Term Debt	8.64	7.78	9.26	9.01	9.14	8.69	9.22	13.95	13.78	13.98
Trade Payables	17.76	9.82	16.36	66.37	42.64	9.02	3.15	7.18	5.15	3.55
Others Liabilities ⓘ	1.87	7.62	4.73	8.31	7.15	15.94	7	5.27	5.55	4.93
Total Liabilities ⓘ	54.22	52.49	55.53	106.41	82.77	58.02	49.88	56.45	56.63	56.30
Fixed Assets
Gross Block	28.16	27.47	28.52	30.79	30.84	30.98	34.58	36.48	36.97	37.28
Accumulated Depreciation	9.85	12.30	14.88	17.28	18.99	20.46	21.39	23.15	24.75	26.29
Net Fixed Assetsⓘ	18.32	15.18	13.64	13.51	11.85	10.52	13.19	13.33	12.22	10.99
CWIP ⓘ	0	0	0	0	0.29	1	0	0.55	0.92	1.63
Investmentsⓘ	0	0	0	0	0	0	0	0	1.42	1.62
Inventories	5.63	8.15	11.03	18.62	18.64	16.43	11.87	17.49	17.50	18.50
Trade Receivables	27.40	25.48	15.65	71.17	48.43	25.45	20.73	22.86	16.35	21.07
Cash Equivalents	0.05	0.04	0.23	0.06	0.18	0.04	0.06	0.06	0.10	0.17
Others Assetsⓘ	2.82	3.65	14.97	3.06	3.37	4.58	4.03	2.16	8.13	2.33
Total Assets ⓘ	54.22	52.49	55.53	106.41	82.77	58.02	49.88	56.45	56.63	56.30

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	1.75	3.61	1.70	6.88	1.19	2.48	1.62	0.77	2.24	1.96
PBT ⓘ	1.05	2.96	0.65	0.64	0.44	0.46	4.29	2.25	1.13	0.56
Adjustment ⓘ	6.34	5.49	2.58	4.19	3.20	2.90	2.60	3.17	3.15	3.12
Changes in Working Capital ⓘ	-5.04	-3.66	-1.13	2.42	-2.33	-0.76	-4.81	-3.97	-1.68	-1.51
Tax Paid ⓘ	-0.60	-1.17	-0.39	-0.38	-0.12	-0.12	-0.47	-0.67	-0.35	-0.20
Cash Flow From Investing Activity ⓘ	-1.10	0.23	-1.04	-2.21	-0.34	-0.84	-3.67	-2.44	-2.27	-1.21
Capex	-1.10	0.23	-1.04	-2.28	-0.35	-0.85	-3.67	-2.46	-0.86	-1.02
Net Investments	0	0	0	0.05	0	0.01	0.01	0.01	-1.41	-0.19
Others ⓘ	0	0	0	0.02	0.01	0	0	0	0	0
Cash Flow From Financing Activityⓘ	-0.70	-3.86	-3.94	-4.80	-0.73	-1.79	2.07	1.68	0.05	-0.69
Net Proceeds from Shares ⓘ	0	0	0	2.97	0	0.88	0	0	1.89	0.68
Net Proceeds from Borrowing ⓘ	-0.99	-0.43	0	0	-2.72	0.19	-0.27	-1.27	-0.68	-0.99
Interest Paid ⓘ	-2.72	-2.57	-2.36	-1.71	-1.49	-1.45	-1.25	-1.41	-1.56	-1.59
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	3.01	-0.85	-1.58	-6.05	3.48	-1.41	3.59	4.36	0.40	1.21
Net Cash Flow ⓘ	-0.06	-0.01	-3.28	-0.13	0.12	-0.15	0.02	0.01	0.03	0.06

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	5.37	12.32	0.94	1.69	1.92	1.41	13.06	5.77	3	1.29
ROCE (%)	11.33	15.9	8.84	7.49	6.17	6.06	15.69	9.3	5.97	4.47
Asset Turnover Ratio	0.81	0.95	1.06	0.64	0.51	0.73	0.95	1.11	0.91	0.77
PAT to CFO Conversion(x)	2.5	2.06	10.63	21.5	2.9	7.52	0.49	0.48	2.52	4.67
Working Capital Days
Receivable Days	202	190	131	306	454	263	164	135	139	158
Inventory Days	48	50	61	104	141	125	101	91	124	152
Payable Days	204	211	128	444	644	354	81	70	78	59

Concord Drugs Ltd Stock News

Concord Drugs Ltd FAQs

What is the share price of Concord Drugs?

Company share prices are keep on changing according to the market conditions. The closing price of Concord Drugs on 24-Dec-2024 16:59 is ₹37.59.

What is the market cap of Concord Drugs?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 24-Dec-2024 16:59 the market cap of Concord Drugs stood at ₹37.59.